Healthcare is where AI's progress is easiest to count — because every clinical AI tool clears a regulator before it reaches a patient. In most industries adoption is fuzzy: a model ships inside a product and you infer its impact. In medicine there is a public list, a clearance date, and a category. The trend line is steep, and it tells you something useful about how serious AI gets deployed everywhere else.
The numbers
- As of July 2025, the FDA lists 1,250+ AI-enabled medical devices — up from ~950 in August 2024.
- Clearances are up roughly 350% in five years.
- Radiology dominates, then cardiology and neurology. Median clearance time in 2025: 142 days.
The radiology concentration is not an accident. Imaging is data-rich, the inputs are standardised, and the "right answer" is well defined — a tumour is either present or it is not. That combination of clean data and a clear ground truth is exactly what makes a problem tractable for machine learning, in medicine and out of it. Where the data is messy and the correct answer is contested, clearances are far rarer.
The median clearance time of 142 days is worth sitting with. In software terms that is glacial — most teams ship features in days. But it is the price of a system that demands evidence before deployment, and it produces something the consumer-software world mostly lacks: a public, auditable record of what works. Every entry on that FDA list is a tool that had to demonstrate it was safe and effective on real data before it touched a patient. The 350% growth over five years is therefore not hype; it is 350% more tools that cleared that bar. That is a very different signal from "350% more AI products launched."
What's actually shipping
Approved devices are overwhelmingly assistive, not autonomous — flagging abnormalities for a radiologist to confirm, guiding a surgeon, supporting bedside evaluation. A human stays in the decision, by design and regulation. The model narrows attention and catches what a tired clinician might miss; the clinician carries the accountability. That division of labour is the single most important design pattern in the whole field, and it generalises far beyond hospitals.
It is worth being clear about why "assistive" is not a euphemism for "unambitious." An assistive tool that reliably catches the early-stage tumour a fatigued radiologist would have missed on the last scan of a long shift is enormously valuable — arguably more so than a fully autonomous system nobody trusts enough to deploy. The constraint of keeping a human accountable does not shrink the impact; it changes its shape. The model does the tireless, high-recall first pass; the human brings context, judgement and responsibility. That pairing is more powerful than either alone, and it is the template for AI in any domain where being wrong has real consequences.
The other reason this matters: liability and trust travel together. A clearance is not just a safety certificate, it is a statement about who is answerable when something goes wrong. By keeping a qualified human in the loop, the system keeps accountability somewhere a patient can actually direct it. Autonomous systems blur that line, which is precisely why regulators have been slow to clear them and why the cleared list skews so heavily assistive.
Healthcare AI advances at the speed of evidence and oversight. That's not a brake on innovation — it's what makes it trustworthy.
The design lesson for everyone else
The FDA's Predetermined Change Control Plan — pre-authorising how a model may evolve after clearance — is a preview of how every regulated industry will handle software that learns. Instead of re-certifying a system every time it retrains, you agree the boundaries of acceptable change up front and monitor against them. Expect the same logic to spread to finance, insurance and any domain where a model's output carries real consequences.
For teams building AI in any high-stakes setting, the healthcare playbook is worth copying directly:
- Pick problems with clean inputs and a checkable answer first. That is where AI earns trust fastest.
- Ship assistive, not autonomous. Keep a qualified human accountable for the decision, especially anything irreversible — the same human-in-the-loop principle the regulators enforce.
- Plan for the model to change. Define in advance how it may be updated and how you will detect drift, rather than treating the launch version as final.
- Log everything. Evidence is what makes the system defensible when something goes wrong.
None of this slows good products down. It is what lets them survive contact with reality. If you're building AI for a regulated or high-consequence workflow, see how we approach it or start a conversation.
Sources
- IntuitionLabs — FDA AI/ML medical device tracker
- Stanford HAI — 2025 AI Index